On August 4, 2022, the company announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).
Kewaunee Scientific Q1 EPS $(0.27) Up From $(0.48) YoY, Sales $50.12M Up From $39.49M YoY
Kewaunee Scientific (NASDAQ:KEQU) reported quarterly losses of $(0.27) per share. This is a 43.75 percent increase over losses of $(0.48) per share from the same period last year. The company reported $50.12 million in
